Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 6/20 | 0.51 |
| ▸ | CCND3 | P30281 | 6/20 | 0.49 |
| ▸ | CDK4 | P11802 | 6/20 | 0.49 |
| ▸ | CCND1 | P24385 | 5/20 | 0.49 |
| ▸ | CCND2 | P30279 | 1/20 | 0.49 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 6/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.48 |
| ▸ | CDK6 | Q00534 | 5/20 | 0.48 |
| ▸ | CDK1 | P06493 | 3/20 | 0.48 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.48 |
| ▸ | CDK7 | P50613 | 3/20 | 0.48 |
| ▸ | CCNH | P51946 | 3/20 | 0.48 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.48 |
| ▸ | CDK9 | P50750 | 3/20 | 0.48 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.48 |
| ▸ | CCNK | O75909 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4070490 | 0.90 | CDK4 (0.45) | SYKCCND3CDK4CCND1CDK2 | |
| SCHEMBL4065950 | 0.89 | SYK (0.53) | SYKCCND3CDK4CCND1CCND2 | |
| SCHEMBL4071068 | 0.89 | SYK (0.51) | SYKCCND3CDK4CCND1CCND2 | |
| SCHEMBL4063982 | 0.88 | SYK (0.56) | SYKCCND3CDK4CCND1CCND2 | |
| SCHEMBL4071098 | 0.87 | SYK (0.49) | SYKCCND3CDK4CCND1CCND2 | |
| SCHEMBL4182326 | 0.87 | SYK (0.51) | SYKCCND3CDK4CCND1CDK2 | |
| SCHEMBL4071154 | 0.86 | SYK (0.53) | SYKCCND3CDK4CCND1CCND2 | |
| SCHEMBL4071155 | 0.86 | SYK (0.53) | SYKCCND3CDK4CCND1CCND2 | |
| SCHEMBL13812732 | 0.86 | SYK (0.51) | SYKCCND3CDK4CCND1CCND2 | |
| SCHEMBL4065296 | 0.85 | CDK4 (0.51) | SYKCCND3CDK4CCND1CCND2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1590341-B1 | 2-AMINOPYRIDINE SUBSTITUTED HETEROCYCLES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER LAMBERT CO (US) | 2009-06-17 | — | — | EP | claimed |
| US-20040236084-A1 | E.g., 4-Cyclopentylamino-2-(5-piperazin-1-yl-pyridin-2-ylamino)-pyrimidine-5-carbonitrile; potent inhibitors of cyclin-dependent kinases useful in treating cell proliferative disorders | PFIZER INC | 2004-11-25 | — | — | US | claimed |
| EP-1590341-B1 | 2-AMINOPYRIDINE SUBSTITUTED HETEROCYCLES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER LAMBERT CO (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20090030005-A1 | Combinations for the treatment of cancer | AMGEN INC. (US) | 2009-01-29 | — | — | US | disclosed |
| EP-1740184-A1 | COMBINATIONS OF SIGNAL TRANSDUCTION INHIBITORS | Pfizer Products Incorporated (US) | 2007-01-10 | — | — | EP | disclosed |
| EP-1590341-A1 | 2-AMINOPYRIDINE SUBSTITUTED HETEROCYCLES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 2005-11-02 | — | — | EP | disclosed |
| WO-2005094830-A1 | COMBINATIONS OF SIGNAL TRANSDUCTION INHIBITORS | PFIZER PRODUCTS INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| US-20050222163-A1 | Combinations of signal transduction inhibitors | PFIZER INC | 2005-10-06 | — | — | US | disclosed |
| US-20040236084-A1 | E.g., 4-Cyclopentylamino-2-(5-piperazin-1-yl-pyridin-2-ylamino)-pyrimidine-5-carbonitrile; potent inhibitors of cyclin-dependent kinases useful in treating cell proliferative disorders | PFIZER INC | 2004-11-25 | — | — | US | disclosed |
| WO-2004065378-A1 | 2-AMINOPYRIDINE SUBSTITUTED HETEROCYCLES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY LLC (US) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040236084-A1 | E.g., 4-Cyclopentylamino-2-(5-piperazin-1-yl-pyridin-2-ylamino)-pyrimidine-5-carbonitrile; potent inhibitors of cyclin-dependent kinases useful in treating cell proliferative disorders | CDK4, CCNA1, CCNI | SYK 2974/4885CCND3 32/4885CDK4 1/4885 |
| US-20050222163-A1 | Combinations of signal transduction inhibitors | CDK4, CDK3, CDK2 | SYK 354/4885CCND3 103/4885CDK4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.